{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-007212","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.648580+00:00","generated_at":"2026-05-27T06:41:56.469518+00:00","sec_items":["2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ironwood cuts workforce ~50%, promotes Gregory Martini to CFO","bullets":["Workforce reduction of ~50% approved Jan 17, targeting primarily field-based sales employees; affected employees notified Jan 29.","Expects to incur $20M-$25M in charges, mostly severance and benefits, substantially in H1 2025; post-reduction headcount ~120.","Gregory Martini promoted to SVP, CFO effective Jan 27; succeeds Thomas McCourt who remains CEO.","Martini receives base salary $485k, bonus target 45%, and 111,111 RSUs vesting over 4 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-007212","json":"https://secwatch.observer/filing/0001104659-25-007212.json","markdown":"https://secwatch.observer/filing/0001104659-25-007212.md","text":"https://secwatch.observer/filing/0001104659-25-007212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/tm254830d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T06:41:56.469518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b21fc87c97","claim":"Gregory Martini was appointed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.","evidence_excerpt":"the Company announced the promotion of Gregory Martini, 36, to Senior Vice President, Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ced304958a","claim":"Thomas McCourt changed role as principal executive officer at IRONWOOD PHARMACEUTICALS INC.","evidence_excerpt":"Mr. Martini will assume the responsibilities of the Company’s principal financial officer from Thomas McCourt, who will remain the Company’s principal executive officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"relinquished principal financial officer role"},{"label":"Role","value":"principal executive officer"}],"fact_type":"executive_change"},{"claim_id":"e826fa88aa84689e7771a075a3b8c6bc3c01d754","claim":"IRONWOOD PHARMACEUTICALS INC announced a restructuring with charges of approximately $20.0 million to approximately $25.0 million (approximately 50%).","evidence_excerpt":"to have approximately 120 full-time employees. The Company estimates that, in connection with this reduction in its workforce, it will incur aggregate charges of approximately $20.0 million to approximately $25.0 million, primarily comprised of one-time employee severance and benefit costs. The charges related to the reduction in workforce are expected to be","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925007212/0001104659-25-007212-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $20.0 million to approximately $25.0 million"},{"label":"Headcount","value":"approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}